1. EYLEA (aflibercept solution for injection) Summary of Product Characteristics, June 2025.

2. Do, D. V., Wykoff, C. C., Sivaprasad, S., et al. (2025). Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial. Ophthalmology, Published November 10, 2025. https://www.aaojournal.org/article/S0161-6420%2825%2900707-9/fulltext

3. Korobelnik JF, Lanzetta P, Leal S, et al. Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial. Ophthalmology. 2026;133(1):39-50. Available from: https://www.aaojournal.org/article/S0161-6420%2825%2900532-9/fulltext